SCHEMBL10115573

SCHEMBL10115573

CC(C)(C)S(=O)(=O)NC1CCN(C(=O)Nc2ccc(Cl)c(Cl)c2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.57
CYP2D6 P10635 1/20 0.57
CYP2C19 P33261 1/20 0.57
NPC1 O15118 2/20 0.56
RAB9A P51151 2/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
LMNA P02545 3/20 0.53
TP53 P04637 3/20 0.53
MAPT P10636 3/20 0.53
EPHX2 P34913 1/20 0.51
PAK1 Q13153 1/20 0.50
CCR2 P41597 7/20 0.49
KCNH2 Q12809 6/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
HPGD P15428 1/20 0.49
TSHR P16473 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
HTT P42858 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10115585 0.88 SMN1; SMN2 (0.53) MAPTSMN1; SMN2HPGDL3MBTL1
SCHEMBL10115550 0.87 ALOX5 (0.56) CYP3A4NPC1RAB9AKMT2ALMNA
SCHEMBL10115594 0.85 MEN1 (0.59) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL10133274 0.85 HSD11B1 (0.44) CYP3A4CYP2D6CYP2C19NPC1RAB9A
SCHEMBL10115557 0.85 HSD11B1 (0.44) CYP3A4CYP2D6CYP2C19NPC1RAB9A
SCHEMBL10115710 0.84 LMNA (0.46) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL10115891 0.84 CYP3A4 (0.57) CYP3A4CYP2D6CYP2C19NPC1RAB9A
SCHEMBL10115527 0.83 LMNA (0.66) NPC1RAB9AKMT2ALMNAMAPT
SCHEMBL12882021 0.83 LMNA (0.53) MEN1KMT2ALMNAEPHX2TSHR
SCHEMBL10115617 0.83 LMNA (0.53) MEN1KMT2ALMNATP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-20110039802-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2011-02-17 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015762-A1 NPY Y5 antagonist NPY5R, NPY1R, NPY2R CYP3A4 1628/4885CYP2D6 1239/4885CYP2C19 1251/4885
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R CYP3A4 1677/4885CYP2D6 1435/4885CYP2C19 1491/4885
US-20110039802-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R CYP3A4 1560/4885CYP2D6 1164/4885CYP2C19 1159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.